The potential of low-dose-rate brachytherapy with iodine-125 in the treatment of local recurrences of prostate cancer after primary high-dose-rate monotherapy.
LDR brachytherapy
recurrence prostate cancer
salvage brachytherapy
Journal
Journal of contemporary brachytherapy
ISSN: 1689-832X
Titre abrégé: J Contemp Brachytherapy
Pays: Poland
ID NLM: 101506276
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
01
09
2022
accepted:
24
03
2023
medline:
22
5
2023
pubmed:
22
5
2023
entrez:
22
5
2023
Statut:
ppublish
Résumé
The incidence of local prostate cancer recurrences after monotherapy with high-dose-rate brachytherapy (HDR-BT) is low. However, a cumulated number of local recurrences during follow-up is naturally observed in highly specialized oncological centers. This retrospective study aimed to present the treatment of local recurrences after HDR-BT with low-dose-rate brachytherapy (LDR-BT). Nine patients with low- and intermediate-risk prostate cancer with a median age of 71 years (range, 59-82 years) were diagnosed with local recurrences after previous monotherapy HDR-BT, 3 × 10.5 Gy (from 2010 to 2013). Median time to biochemical recurrence was 59 months (range, 21-80 months). All patients received 145 Gy with salvage LDR-BT (iodine-125). Gastrointestinal and urological toxicities were evaluated based on patients' records following CTCAE v. 4.0 and IPSS scales. The median follow-up after salvage treatment was 30 months (range, 17-63 months). Local recurrences (LR) were detected in two cases, and the actuarial 2-year local control was 88%. Biochemical failure was observed in four cases. Distant metastases (DM) were observed in 2 patients. In one patient, both LR and DM were diagnosed simultaneously. Four patients had no relapse of the disease, and a 2-year disease-free survival (DSF) was 58.3%. Before salvage treatment, median IPSS scores were 6.5 points (range, 1-23 points). At the first follow-up visit, after one month, the mean IPSS score was 20 points, and at the last follow-up visit, it was 8 points (range, 1-26 points). One patient had urinary retention after treatment. There was no significant change in IPSS scores before and after the treatment ( Salvage LDR-BT for patients with prostate cancer previously treated with HDR-BT monotherapy is characterized by acceptable toxicity, and may result in local disease control.
Identifiants
pubmed: 37215611
doi: 10.5114/jcb.2023.126618
pii: 50544
pmc: PMC10196734
doi:
Types de publication
Journal Article
Langues
eng
Pagination
103-109Informations de copyright
Copyright © 2023 Termedia.
Déclaration de conflit d'intérêts
The authors report no conflict of interest.
Références
Cancer. 2007 Oct 1;110(7):1485-92
pubmed: 17701957
J Radiat Res. 1979 Dec;20(4):259-63
pubmed: 536948
J Biol Chem. 2004 Nov 26;279(48):49624-32
pubmed: 15377658
J Contemp Brachytherapy. 2021 Feb;13(1):12-17
pubmed: 34025731
J Urol. 2006 Nov;176(5):2020-4
pubmed: 17070243
Brachytherapy. 2014 Nov-Dec;13(6):529-41
pubmed: 25085454
FEBS Lett. 1994 Oct 24;353(3):297-300
pubmed: 7957879
J Natl Compr Canc Netw. 2021 Feb 02;19(2):134-143
pubmed: 33545689
Radiother Oncol. 2016 Jun;119(3):405-10
pubmed: 27165612
Transl Androl Urol. 2018 Jun;7(3):414-435
pubmed: 30050801
Brachytherapy. 2017 Nov - Dec;16(6):1091-1098
pubmed: 28838648
Eur Urol. 2015 May;67(5):825-36
pubmed: 25097095
Med Phys. 2012 Jun;39(6):3189-201
pubmed: 22755703
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):270-277
pubmed: 29102279
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74
pubmed: 16798415
Int J Biol Sci. 2020 Feb 4;16(7):1096-1106
pubmed: 32174787
Crit Rev Oncog. 2018;23(1-2):39-67
pubmed: 29953367
Prostate Cancer Prostatic Dis. 2019 May;22(2):309-316
pubmed: 30385835
Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):195-201
pubmed: 20381268
Radiother Oncol. 2020 May;146:16-20
pubmed: 32086047
Radiat Res. 1979 Sep;79(3):552-67
pubmed: 482612
Int J Radiat Oncol Biol Phys. 1992;23(1):81-7
pubmed: 1572833
Int J Radiat Oncol Biol Phys. 1995 May 15;32(2):373-8
pubmed: 7751179